Boehringer Ingelheim significantly expands its supply center for China

Boehringer IngelheimBoehringer Ingelheim intends to invest 70 million Euro to expand its manufacturing plant in the Zhangjiang High-Tech Park in Shanghai into a strategically important supply center for China. The goal of this project is to bring more health to more patients and to continuously improve Boehringer Ingelheim's product competitiveness and enlarge its market share.

With the expansion until end of 2013, the number of employees will rise significantly from 240 today to 400, the production capacity will be doubled.

"We want to expand our Zhangjiang plant, primarily to meet the demand for more health in China. It also shows our continuous commitment to China and specifically Shanghai", said Professor Dr Wolfram Carius, responsible for the Corporate Board Division Operations and Human Resources. "Our vision is to transform our Shanghai plant into a launch site in Boehringer Ingelheim's global Operations network."

The project intends to build a modular and lean manufacturing facility on the current production site. It will be able to produce marketed products and new pipeline products. The objective to have world-class production through a lean manufacturing approach will be supported by the optimisation of material flow and by our highly qualified employees.

In the first phase, which will be completed by the end of December 2013, a packaging center for ampoules and solids and a new automatic warehouse will be constructed. Furthermore, a new laboratory building for development activities will be set up on the site. In the second phase, to be concluded until the end of 2014, the existing solids manufacturing facility will be revamped and upgraded with new technologies.

The pharmaceutical industry is currently in the focus of Shanghai's economic strategy. Boehringer Ingelheim China’s strategy is in tune with the economic structure transformation advocated by the government and will lead the company into a new phase of development. "We are committed to meeting the growing demand of China's pharmaceutical market and to bringing more health to patients and their families", said David Preston, Chief Executive Officer of Boehringer Ingelheim China.

Since it entered the Chinese market in 1994, Boehringer Ingelheim has expanded its product range to cover respiratory, cardiovascular, central nervous system and other important therapeutic areas. In the forthcoming years, the company will continue to expand, including the therapeutic areas diabetes, oncology and stroke prevention.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]